Related Experiment Video
Updated: Mar 27, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant
Antonello Veccia1, Orazio Caffo1, Ugo De Giorgi2
1Medical Oncology Department, Santa Chiara Hospital, Largo Medaglie d'Oro, 38100 Trento, Italy.
Aim:
To assess clinical outcomes in octogenarians treated with docetaxel (DOC) for metastatic castration-resistant prostate cancer.
Patients & Methods:
The multicenter retrospective study was based on a review of the pre- and post-DOC clinical history, DOC treatment and outcomes.
Results:
We reviewed the records of 123 patients (median age: 82 years) who received DOC every 3 weeks or weekly, without significant grade 3-4 toxicities. Median progression-free survival was 7 months; median overall survival from the start of DOC was 20 months, but post-progression treatments significantly prolonged overall survival.
Conclusion:
The findings of this study suggest that toxicity is acceptable, survival is independent of patient's age and survival can be significantly prolonged by the use of new agents.
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Pharmacodynamics in Geriatric Patients: Effects of Age
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

